Just a moment, the page is loading...

Grants and Funding

At Immunocore, we want to radically improve outcomes for patients with cancer, infectious diseases, and autoimmune diseases, by pioneering and delivering transformative immunomodulating medicine.

We recognize that medical science evolves rapidly with new information becoming available constantly. As part of the healthcare system, we also understand the need to support healthcare professionals in their pursuit of research activities and the most current education to provide the best patient care possible. There is further need to support patients, caregivers and communities to ensure that they have the information and medicines or treatments to support healthy, quality, and productive lives.

As such, we are proud to have the opportunity to consider funding applications for:
×


4 Results:


Sponsor Postings ↑ Description Created
 
Cutaneous Melanoma: Rational sequencing or combination strategies addressing mechanisms for overcoming resistance with tebentafusp (primary and/or secondary) 3/17/2025
 
Cutaneous or Uveal Melanoma: Measures to improve patient safety and quality of life (e.g., rational combinations) 3/17/2025
 
Cutaneous or Uveal Melanoma: Special Populations (e.g., patients with autoimmune disorders or heart disease) 3/17/2025
 
Uveal Melanoma: Rational combinations addressing mechanisms for overcoming resistance (primary and/or secondary) to tebentafusp or enhancing tebentafusp activity in 1L metastatic disease 3/17/2025
MM-UK—2500001
Date of production: May 2025